Faculty of Applied Sciences and Biotechnology, Shoolini University, Solan, Himachal Pradesh, 173229, India.
Department of Pharmaceutical Sciences and Chinese Traditional Medicine, Southwest University, Beibei, 400715, Chongqing, People's Republic of China.
Med Oncol. 2023 Oct 3;40(11):314. doi: 10.1007/s12032-023-02171-x.
The fatal amplification of lung cancer across the globe and the limitations of current treatment strategies emphasize the necessity for substitute therapeutics. The incorporation of phyto-derived components in chemo treatment holds promise in addressing those challenges. Despite the significant progressions in lung cancer therapeutics, the complexities of molecular mechanism and pathways underlying this disease remain inadequately understood, necessitating novel biomarker targeting. The Himalayas, abundant in diverse plant varieties with established chemotherapeutic potential, presents a promising avenue for investigating potential cures for lung carcinoma. The vast diversity of phytocompounds herein can be explored for targeting the disease. This review delves into the multifaceted targets of lung cancer and explores the established phytochemicals with their specific molecular targets. It emphasizes comprehending the intricate pathways that govern effective therapeutic interventions for lung cancer. Through this exploration of Himalayan flora, this review seeks to illuminate potential breakthroughs in lung cancer management using natural compounds. The amalgamation of Himalayan plant-derived compounds with cautiously designed combined therapeutic approaches such as nanocarrier-mediated drug delivery and synergistic therapy offers an opportunity to redefine the boundaries of lung cancer treatment by reducing the drug resistance and side effects and enabling an effective targeted delivery of drugs. Furthermore, additional studies are obligatory to understand the possible derivation of natural compounds used in current lung cancer treatment from plant species within the Himalayan region.
全球范围内肺癌的致命性扩增以及当前治疗策略的局限性强调了替代治疗的必要性。植物衍生成分在化疗中的结合有望解决这些挑战。尽管在肺癌治疗方面取得了重大进展,但该疾病的分子机制和途径的复杂性仍未得到充分理解,需要新的生物标志物靶向治疗。喜马拉雅山脉拥有丰富的、具有已确立化疗潜力的多种植物品种,为研究治疗肺癌的潜在方法提供了有前途的途径。这里丰富多样的植物化合物可以用来针对这种疾病。这篇综述深入探讨了肺癌的多方面靶点,并研究了已确立的具有特定分子靶点的植物化学物质。它强调了理解控制肺癌有效治疗干预的复杂途径的重要性。通过对喜马拉雅植物群的探索,本综述旨在探讨利用天然化合物管理肺癌的潜在突破。喜马拉雅植物衍生化合物与精心设计的联合治疗方法(如纳米载体介导的药物递送和协同治疗)的结合,为减少耐药性和副作用以及实现药物的有效靶向递送提供了机会,从而有可能重新定义肺癌治疗的界限。此外,还需要进行更多的研究来了解当前用于治疗肺癌的天然化合物可能是从喜马拉雅地区的植物物种中衍生而来的。
Med Oncol. 2023-10-3
J Ethnopharmacol. 2021-3-25
J Ethnopharmacol. 2023-12-5
Anticancer Agents Med Chem. 2022
Pharmaceuticals (Basel). 2024-9-30
Drug Des Devel Ther. 2024
Naunyn Schmiedebergs Arch Pharmacol. 2024-8
J Funct Biomater. 2022-10-28
Polymers (Basel). 2022-7-26
Biomolecules. 2021-10-18